| Companies sponsors |
AstraZeneca (durvalumab, tremelimumab) |
| Others |
Department of Health and Social Care |
| |
NHS England |
| Patient carer groups |
Addenbrookes Liver Transplant Association |
| |
Black Health Agency for Equality |
| |
British Liver Trust |
| |
Cancer Black Care |
| |
Cancer Equality |
| |
Cancer 52 |
| |
GUTS UK |
| |
Haemochromatosis UK |
| |
Helen Rollason Cancer Charity |
| |
Independent Cancer Patients’ Voice |
| |
Liver4Life |
| |
Macmillan Cancer Support |
| |
Maggie’s Centres |
| |
Marie Curie |
| |
Pelican Cancer Foundation |
| |
South Asian Health Foundation |
| |
Specialised Healthcare Alliance |
| |
Tenovus Cancer Care |
| |
The Hepatitis C Trust |
| Professional groups |
Association of Anaesthetists of Great Britain & Ireland |
| |
Association of Cancer Physicians |
| |
Association of Surgeons of Great Britain & Ireland |
| |
British Association of the Study of the Liver (BASL) / HCC UK |
| |
British Geriatrics Society |
| |
British Institute of Radiologists |
| |
British Oncology Pharmacy Association |
| |
British Psychosocial Oncology Society |
| |
British Society of Gastroenterology |
| |
Cancer Research UK |
| |
Hepatitis Nurse Specialist Forum |
| |
Royal College of Anaesthetists |
| |
Royal College of General Practitioners |
| |
Royal College of Nursing |
| |
Royal College of Pathologists |
| |
Royal College of Physicians |
| |
Royal College of Radiologists |
| |
Royal College of Surgeons |
| |
Royal Pharmaceutical Society |
| |
Royal Society of Medicine |
| |
Society and College of Radiologists |
| |
UK Clinical Pharmacy Association |
| |
UK Oncology Nursing Society |
| Associated guideline groups |
NICE - National Guideline Alliance (cancer, mental health, and women and children’s health) |
| Associated public health groups |
Public Health Wales |
| |
UK Health Security Agency |
| Comparator companies |
Bayer (sorafenib) |
| |
Boston Scientific (TheraSphere) |
| |
Celltrion Healthcare (bevacizumab) |
| |
Dr. Reddy’s Laboratories (bevacizumab) |
| |
Eisai (lenvatinib) |
| |
Organon Pharma (bevacizumab) |
| |
Pfizer (bevacizumab) |
| |
Roche (atezolizumab, bevacizumab) |
| |
Sandoz (sorafenib) |
| |
Sirtex (SIR-Spheres) |
| |
Terumo Europe (QuirumSpheres) |
| |
Thornton and Ross (bevacizumab, sorafenib) |
| |
Zentiva (bevacizumab, sorafenib) |
| Evidence review group |
National Institute for Health Research Health Technology Assessment Programme (NETSCC) |
| |
Warwick Evidence |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
Allied Health Professionals Federation |
| |
Board of Community Health Councils in Wales |
| |
British National Formulary |
| |
Care Quality Commission |
| |
Department of Health, Social Services and Public Safety for Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Medicines and Healthcare products Regulatory Agency |
| |
National Association of Primary Care |
| |
National Pharmacy Association |
| |
NHS Confederation |
| |
Scottish Medicines Consortium |
| |
Welsh Government |
| |
Welsh Health Specialised Services Committee |
| Relevant research groups |
Cochrane Hepato-biliary Group |
| |
Cochrane Infectious Diseases Group |
| |
Cochrane UK |
| |
Foundation for Liver Research |
| |
Genomics England |
| |
Institute of Cancer Research |
| |
MRC Clinical Trials Unit |
| |
National Institute for Health Research |